Fact based stock research
Raffles Medical Group (SGX:BSL)
SG1CH4000003
Raffles Medical Group stock research in summary
rafflesmedicalgroup.com/raffles-medical-group
Raffles Medical Group shares are less expensive than other comparable stocks. While they are good value, they are riskily financed, and show below average growth. We recommend evaluating whether the future of the company Raffles Medical Group is really as difficult as the low price of the stock suggests. If you believe that the future of the company is market-typical or even better, then this could be an argument for a share purchase.
Latest Obermatt Ranks
| Value Rank | 76 |  |
| Growth Rank | 18 |  |
| Safety Rank | 47 |  |
| Combined Rank | 44 | |
| Country | Singapore |
| Industry | Health Care Facilities |
| Index | |
| Size class | Medium |
March 26, 2021. Stock data may be delayed. Login to get the most recent research.
Google: Raffles Medical Group
Research History: Raffles Medical Group
| RESEARCH HISTORY | 2018 | 2019 | 2020 | 2021 | ||||
|---|---|---|---|---|---|---|---|---|
| VALUE | ||||||||
| VALUE | n/a |
|
n/a |
|
65 |
|
76 |
|
| GROWTH | ||||||||
| GROWTH | n/a |
|
n/a |
|
24 |
|
18 |
|
| SAFETY | ||||||||
| SAFETY | n/a |
|
n/a |
|
41 |
|
47 |
|
| COMBINED | ||||||||
| COMBINED | n/a |
|
n/a |
|
37 |
|
44 |
|
Value Metrics in Detail
| VALUE METRICS | 2018 | 2019 | 2020 | 2021 | ||||
|---|---|---|---|---|---|---|---|---|
| PRICE VS. REVENUES (P/S) | ||||||||
| PRICE VS. REVENUES (P/S) | n/a |
|
n/a |
|
40 |
|
47 |
|
| PRICE VS. PROFITS (P/E) | ||||||||
| PRICE VS. PROFITS (P/E) | n/a |
|
n/a |
|
58 |
|
53 |
|
| PRICE VS. CAPITAL (Market-to-Book) | ||||||||
| PRICE VS. CAPITAL (Market-to-Book) | n/a |
|
n/a |
|
67 |
|
68 |
|
| DIVIDEND YIELD | ||||||||
| DIVIDEND YIELD | n/a |
|
n/a |
|
80 |
|
92 |
|
| CONSOLIDATED RANK: VALUE | ||||||||
| CONSOLIDATED RANK: VALUE | n/a |
|
n/a |
|
65 |
|
76 |
|
Growth Metrics in Detail
| GROWTH METRICS | 2018 | 2019 | 2020 | 2021 | ||||
|---|---|---|---|---|---|---|---|---|
| REVENUE GROWTH | ||||||||
| REVENUE GROWTH | n/a |
|
n/a |
|
34 |
|
35 |
|
| PROFIT GROWTH | ||||||||
| PROFIT GROWTH | n/a |
|
n/a |
|
24 |
|
26 |
|
| STOCK RETURNS | ||||||||
| STOCK RETURNS | n/a |
|
n/a |
|
27 |
|
36 |
|
| CONSOLIDATED RANK: GROWTH | ||||||||
| CONSOLIDATED RANK: GROWTH | n/a |
|
n/a |
|
24 |
|
18 |
|
Safety Metrics in Detail
| SAFETY METRICS | 2018 | 2019 | 2020 | 2021 | ||||
|---|---|---|---|---|---|---|---|---|
| LEVERAGE | ||||||||
| LEVERAGE | n/a |
|
n/a |
|
53 |
|
60 |
|
| REFINANCING | ||||||||
| REFINANCING | n/a |
|
n/a |
|
16 |
|
20 |
|
| LIQUIDITY | ||||||||
| LIQUIDITY | n/a |
|
n/a |
|
66 |
|
88 |
|
| CONSOLIDATED RANK: SAFETY | ||||||||
| CONSOLIDATED RANK: SAFETY | n/a |
|
n/a |
|
41 |
|
47 |
|
Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Raffles Medical Group from March 26, 2021.
We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.